Kenneth Fromkin, MD

Appointed
2001

Education & Fellowships

Fellowship - New York Presbyterian Hospital - Columbia Univ. & Weill Cornell Medical Center
Interventional Cardiology
New York, NY
2001

Fellowship - New York Presbyterian Hospital - Columbia Univ. & Weill Cornell Medical Center
Cardiovascular Disease
New York, NY
2000

Residency - Yale-New Haven Hospital
Internal Medicine
New Haven, CT
1997

Internship - Yale-New Haven Hospital
Internal Medicine
New Haven, CT
1995

Medical Education - University of Chicago Pritzker School of Medicine
Chicago, IL
1994

Undergraduate - Johns Hopkins University
Baltimore, MD
1990

Professional Highlights

• Director of Invasive and Interventional Cardiology, Cleveland Clinic Florida

Certifications

• Internal Medicine - Interventional Cardiology
• Internal Medicine - Cardiovascular Disease

Specialty Interests

Coronary Artery Angiography, Left and Right Cardiac Catheterization, Angioplasty, Stenting, Drug Eluting Stenting, IVUS, FFR, Intra-Aortic Balloon Pump Insertion, Rotational Atherectomy, Rheolytic Thrombectomy, Complex coronary artery interventions, chronic total occlusions, Subclavian, Renal, Iliac, Femoral, and Upper and Lower Extremity Angiography and Endovascular Interventional Arterial Procedures, complex lower extremity arterial interventions

Awards & Honors

• Regional Castle Connolly Top Doctor, Interventional Cardiology, 2008-2011
• America's Top Cardiologists, Consumer's Research Council of America, 2007-2011

Innovations & Patents

• Dr. Fromkin has been involved in some of the original studies of the hybrid coronary artery revascularization strategy which combines an interventional cardiology approach with a minimally invasive surgical approach to address multivessel coronary artery disease. In this treatment strategy, PCI and stenting of non-LAD vessels is combined with single-vessel minimally invasive closed chest robotic bypass surgery to achieve complete coronary artery revascularization without the need for traditional open chest bypass surgery. This research was highlighted at the American College of Cardiology's 52nd Annual Scientific Session at a press conference showcasing the most noteworthy abstracts presented at that meeting. Many patients with multivessel coronary artery disease have been helped by this strategy of revascularization and have avoided sternotomy while still having all of their coronary artery lesions addressed.

Memberships

• American College of Cardiology
• Society of Coronary Angiographers and Interventionists
• American Medical Association
• Broward County Medical Association

See publications for Kenneth Fromkin, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 9/18/2024, Dr. Fromkin has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.